Clearance of Piperacillin-Tazobactam and Vancomycin during Continuous Renal Replacement with Regional Citrate Anticoagulation
Date
2023
Authors
Sharrock, L.
Ankravs, M.J.
Deane, A.M.
Rechnitzer, T.
Wallis, S.C.
Roberts, J.A.
Bellomo, R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Therapeutic Drug Monitoring, 2023; 45(2):265-268
Statement of Responsibility
Lucy Sharrock, Melissa J. Ankravs, Adam M. Deane, Thomas Rechnitzer, Steven C. Wallis, Jason A. Roberts and Rinaldo Bellomo
Conference Name
Abstract
Background: The use of regional citrate anticoagulation during continuous venovenous hemodiafiltration (CVVHDF) has increased worldwide. However, data on its effect on the pharmacokinetics of antibiotics are limited. In this study, the authors aimed to measure the clearance of piperacillin–tazobactam and vancomycin in patients receiving CVVHDF with regional citrate anticoagulation. Methods: This study measured piperacillin–tazobactam and vancomycin concentrations in patients receiving CVVHDF with regional citrate anticoagulation. Dosing regimens were independently selected by intensivists. Arterial blood and effluent fluid samples were obtained over a single dosing interval and analyzed using ultra-high-performance liquid chromatography with tandem mass spectrometry. Results: Seventeen sampling intervals in 15 patients (9 receiving piperacillin–tazobactam only, 4 receiving vancomycin only, and 2 receiving both) were used. The median overall clearance for piperacillin was 35.2 mL/min [interquartile range (IQR): 32.2–38.6], 70 mL/min (IQR: 62.7–76.2) for tazobactam, and 29.5 mL/min (IQR: 26.2–32) for vancomycin. Conclusions: This is the first study to quantify the pharmacokinetics of vancomycin and piperacillin–tazobactam in patients receiving CVVHDF with regional citrate anticoagulation. These results indicate high clearance and provide key information to guide optimal dosing.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.